Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111

Sort by

Sort Order Select

Journal Articles

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-CD19 CART Therapy for Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 2416.

https://doi.org/10.1182/blood-2023-187524

Published: 2023

Journal Articles

Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Mazyar Shadman, Matthew J Frigault, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Daniel J. Landsburg, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini

Blood (2023) 142 (Supplement 1): 3497.

https://doi.org/10.1182/blood-2023-180233

Published: 2023

Journal Articles

TP53 Mutations Detected By Clinical Laboratory Mutation Analysis Predict for Inferior Clinical Outcomes in Patients with Newly-Diagnosed Aggressive B Cell Lymphomas, Including Those with High-Risk Features

Daniel J. Landsburg, Jennifer JD Morrissette, Sunita D. Nasta, Stefan K. Barta, Stephen J Schuster, Jakub Svoboda, Elise A. Chong, Adam Bagg

Blood (2023) 142 (Supplement 1): 1739.

https://doi.org/10.1182/blood-2023-186343

Published: 2023

Journal Articles

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Blood (2023) 142 (Supplement 1): 312.

https://doi.org/10.1182/blood-2023-174257

Published: 2023

Journal Articles

Bendamustine Is Less Toxic Than Fludarabine-Cyclophosphamide-Based Lymphodepletion before CD28-Costimulated CART19 through Reduced Inflammatory Cytokines

Blood (2023) 142 (Supplement 1): 4483.

https://doi.org/10.1182/blood-2023-182234

Published: 2023

Journal Articles

Impact of Genetic Mutations on Survival Following Receipt of Commercial CART19 for Patients Diagnosed with Aggressive B Cell Lymphoma

Benjamin Frost, Jennifer JD Morrissette, Stephen J Schuster, Sunita D. Nasta, Jakub Svoboda, Stefan K. Barta, Elise A. Chong, Marco Ruella, Adam Bagg, Daniel J. Landsburg

Blood (2023) 142 (Supplement 1): 3518.

https://doi.org/10.1182/blood-2023-186553

Published: 2023

Journal Articles

Safety of CAR-T Cell Therapy in Asymptomatic Patients with Positive Respiratory Viral Testing Prior to CAR-T Infusions

Reid M. Muenzen, Emeline R. Chong, Dylan Therwhanger, Daniel J. Landsburg, Sunita D. Nasta, Jakub Svoboda, Stefan K. Barta, Mitchell E. Hughes, Elizabeth Weber, Marco Ruella, Noelle V. Frey, David L. Porter, Stephen J. Schuster, Elise A. Chong

Blood (2023) 142 (Supplement 1): 2341.

https://doi.org/10.1182/blood-2023-190434

Published: 2023

Journal Articles

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Blood (2023) 142 (Supplement 1): 308.

https://doi.org/10.1182/blood-2023-183001

Published: 2023

Journal Articles

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Daniel J. Landsburg, Michael Heim, Amy Moskop, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini, Matthew J Frigault

Blood (2023) 142 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2023-179387

Published: 2023

Journal Articles

Impact of Psychological Distress on Immune Phenotype in CLL/SLL Patients Managed By Active Observation

Carolyn Y. Fang, Jakub Svoboda, Adam D. Cohen, Henry C. Fung, Richard I. Fisher, Elizabeth Handorf, Hatcher Ballard, Stefan K. Barta, Daniel J. Landsburg, Dwivedy S. Nasta, Stephen J Schuster, Rashmi Khanal, Alexander W. MacFarlane, Kerry S. Campbell

Blood (2023) 142 (Supplement 1): 6526.

https://doi.org/10.1182/blood-2023-189330

Published: 2023

Journal Articles

CD5 Expression in Mature T Cell Lymphoma

Miao Cao, Montreh Tavakkoli, Elise A. Chong, Jordan S Carter, Marco Ruella, Daniel J. Landsburg, Sunita D. Nasta, Jakub Svoboda, Stephen J Schuster, Stefan K. Barta

Blood (2023) 142 (Supplement 1): 6195.

https://doi.org/10.1182/blood-2023-188043

Published: 2023

Journal Articles

Rituximab, Cyclophosphamide, Etoposide and Prednisone for the Treatment of Post-Transplantation Lymphoproliferative Disorder

Reid M. Muenzen, Mitchell E. Hughes, Sunita Dwivedy Nasta, Jakub Svoboda, Daniel J. Landsburg, Stefan K. Barta, Donald Tsai, Stephen J. Schuster, Elise A. Chong

Blood (2022) 140 (Supplement 1): 6715–6716.

https://doi.org/10.1182/blood-2022-169764

Published: 2022

Journal Articles

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Newly-Diagnosed Germinal Center Aggressive B Cell Lymphoma

Daniel J. Landsburg, Jennifer J.D. Morrissette, Stephen J. Schuster, Sunita Dwivedy Nasta, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Megan S. Lim

Blood (2022) 140 (Supplement 1): 6653–6655.

https://doi.org/10.1182/blood-2022-165056

Published: 2022

Journal Articles

Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404

Jonathon B. Cohen, Opeyemi Jegede, Craig A. Portell, Mehdi Hamadani, Catherine S. Diefenbach, Kevin A. David, Christopher D. Fletcher, Daniel J. Landsburg, Suparna Mantha, Brad S. Kahl

Blood (2022) 140 (Supplement 1): 6487–6488.

https://doi.org/10.1182/blood-2022-164710

Published: 2022

Journal Articles

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with First Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Curative-Intent Immunochemotherapy

Nikita Dave, Jennifer J.D. Morrissette, Stephen J. Schuster, Sunita Dwivedy Nasta, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Megan S. Lim, Daniel J. Landsburg

Blood (2022) 140 (Supplement 1): 6702–6703.

https://doi.org/10.1182/blood-2022-165073

Published: 2022

Journal Articles

Low-Dose Radiation Therapy with Nivolumab in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of the Phase II Radvax Trial

Michael J. LaRiviere, Tina Vaziri, Michael Farwell, Amit Maity, Ima Paydar, Stephen J. Schuster, Sunita Dwivedy Nasta, Elise A. Chong, Daniel J. Landsburg, John P. Plastaras, Jakub Svoboda

Blood (2022) 140 (Supplement 1): 3726–3727.

https://doi.org/10.1182/blood-2022-168975

Published: 2022

Journal Articles

Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Daniel J. Landsburg, Matthew Frigault, Michael Heim, Stephen Ronan Foley, Brian T. Hill, Christine M. Ho, Caron A. Jacobson, Samantha Jaglowski, Frederick L. Locke, Ron Ram, Peter A. Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Marta Majdan, Aisha Masood, Marcelo C Pasquini, Cameron J. Turtle

Blood (2022) 140 (Supplement 1): 1584–1587.

https://doi.org/10.1182/blood-2022-158822

Published: 2022

Journal Articles

Mivavotinib, a Syk Inhibitor, in Relapsed/Refractory (R/R) Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL) with or without MYD88 and/or CD79 Mutations: A Phase 2 Study

Reem Karmali, Daniel J. Landsburg, Jason Westin, John P. Leonard, Emil T. Kuriakose, Bradley James Sumrow, Susheela Carroll, Katherine Albert, Lalith Akella, Leo I. Gordon

Blood (2022) 140 (Supplement 1): 12125–12126.

https://doi.org/10.1182/blood-2022-165502

Published: 2022

Journal Articles

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Palliative-Intent Therapy

Danielle F Soberman, Jennifer J.D. Morrissette, Stephen J. Schuster, Sunita Dwivedy Nasta, James N. Gerson, Stefan K. Barta, Jakub Svoboda, Elise A. Chong, Megan S. Lim, Daniel J. Landsburg

Blood (2022) 140 (Supplement 1): 9514–9515.

https://doi.org/10.1182/blood-2022-165086

Published: 2022

Journal Articles

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Blood (2022) 140 (Supplement 1): 3839–3841.

https://doi.org/10.1182/blood-2022-157105

Published: 2022

NARROW

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-CD19 CART Therapy for Non-Hodgkin Lymphoma

Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

TP53 Mutations Detected By Clinical Laboratory Mutation Analysis Predict for Inferior Clinical Outcomes in Patients with Newly-Diagnosed Aggressive B Cell Lymphomas, Including Those with High-Risk Features

Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US Centers

Bendamustine Is Less Toxic Than Fludarabine-Cyclophosphamide-Based Lymphodepletion before CD28-Costimulated CART19 through Reduced Inflammatory Cytokines

Impact of Genetic Mutations on Survival Following Receipt of Commercial CART19 for Patients Diagnosed with Aggressive B Cell Lymphoma

Safety of CAR-T Cell Therapy in Asymptomatic Patients with Positive Respiratory Viral Testing Prior to CAR-T Infusions

Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Impact of Psychological Distress on Immune Phenotype in CLL/SLL Patients Managed By Active Observation

CD5 Expression in Mature T Cell Lymphoma

Rituximab, Cyclophosphamide, Etoposide and Prednisone for the Treatment of Post-Transplantation Lymphoproliferative Disorder

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Newly-Diagnosed Germinal Center Aggressive B Cell Lymphoma

Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with First Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Curative-Intent Immunochemotherapy

Low-Dose Radiation Therapy with Nivolumab in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of the Phase II Radvax Trial

Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Mivavotinib, a Syk Inhibitor, in Relapsed/Refractory (R/R) Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL) with or without MYD88 and/or CD79 Mutations: A Phase 2 Study

Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Palliative-Intent Therapy

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only